1. Home
  2. NXPL vs CYTH Comparison

NXPL vs CYTH Comparison

Compare NXPL & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXPL
  • CYTH
  • Stock Information
  • Founded
  • NXPL 1997
  • CYTH 1990
  • Country
  • NXPL United States
  • CYTH United States
  • Employees
  • NXPL N/A
  • CYTH N/A
  • Industry
  • NXPL Telecommunications Equipment
  • CYTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXPL Telecommunications
  • CYTH Health Care
  • Exchange
  • NXPL Nasdaq
  • CYTH Nasdaq
  • Market Cap
  • NXPL 21.9M
  • CYTH 20.4M
  • IPO Year
  • NXPL N/A
  • CYTH N/A
  • Fundamental
  • Price
  • NXPL $0.97
  • CYTH $0.71
  • Analyst Decision
  • NXPL
  • CYTH Buy
  • Analyst Count
  • NXPL 0
  • CYTH 3
  • Target Price
  • NXPL N/A
  • CYTH $0.95
  • AVG Volume (30 Days)
  • NXPL 33.1K
  • CYTH 23.7K
  • Earning Date
  • NXPL 11-14-2024
  • CYTH 11-14-2024
  • Dividend Yield
  • NXPL N/A
  • CYTH N/A
  • EPS Growth
  • NXPL N/A
  • CYTH N/A
  • EPS
  • NXPL N/A
  • CYTH N/A
  • Revenue
  • NXPL $66,404,000.00
  • CYTH $1,132,430.00
  • Revenue This Year
  • NXPL N/A
  • CYTH N/A
  • Revenue Next Year
  • NXPL N/A
  • CYTH $24.49
  • P/E Ratio
  • NXPL N/A
  • CYTH N/A
  • Revenue Growth
  • NXPL 498.52
  • CYTH 24.65
  • 52 Week Low
  • NXPL $0.85
  • CYTH $0.59
  • 52 Week High
  • NXPL $2.68
  • CYTH $2.12
  • Technical
  • Relative Strength Index (RSI)
  • NXPL 51.01
  • CYTH 46.91
  • Support Level
  • NXPL $1.09
  • CYTH $0.70
  • Resistance Level
  • NXPL $1.17
  • CYTH $0.77
  • Average True Range (ATR)
  • NXPL 0.07
  • CYTH 0.04
  • MACD
  • NXPL 0.01
  • CYTH -0.00
  • Stochastic Oscillator
  • NXPL 58.76
  • CYTH 28.38

About NXPL NextPlat Corp

NextPlat Corp is a global e-commerce and healthcare company. Its e-commerce venues form an effective global network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operate in two segments: e-Commerce Business and Healthcare Business.

About CYTH Cyclo Therapeutics Inc.

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Share on Social Networks: